RU2013126056A - COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) - Google Patents
COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) Download PDFInfo
- Publication number
- RU2013126056A RU2013126056A RU2013126056/15A RU2013126056A RU2013126056A RU 2013126056 A RU2013126056 A RU 2013126056A RU 2013126056/15 A RU2013126056/15 A RU 2013126056/15A RU 2013126056 A RU2013126056 A RU 2013126056A RU 2013126056 A RU2013126056 A RU 2013126056A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutical composition
- composition according
- binder
- fampridine
- cellulose
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 24
- 239000011230 binding agent Substances 0.000 claims abstract 18
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims abstract 17
- 229960004979 fampridine Drugs 0.000 claims abstract 17
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims abstract 16
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract 16
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims abstract 16
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims abstract 12
- 235000021355 Stearic acid Nutrition 0.000 claims abstract 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract 10
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims abstract 10
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims abstract 10
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 10
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 10
- 239000008117 stearic acid Substances 0.000 claims abstract 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 8
- 239000000454 talc Substances 0.000 claims abstract 5
- 229910052623 talc Inorganic materials 0.000 claims abstract 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims abstract 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims abstract 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract 4
- 229920002472 Starch Polymers 0.000 claims abstract 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims abstract 4
- 239000008116 calcium stearate Substances 0.000 claims abstract 4
- 235000013539 calcium stearate Nutrition 0.000 claims abstract 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims abstract 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract 4
- 229960003943 hypromellose Drugs 0.000 claims abstract 4
- 239000003112 inhibitor Substances 0.000 claims abstract 4
- 239000008101 lactose Substances 0.000 claims abstract 4
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract 4
- 229920000609 methyl cellulose Polymers 0.000 claims abstract 4
- 239000001923 methylcellulose Substances 0.000 claims abstract 4
- 235000010981 methylcellulose Nutrition 0.000 claims abstract 4
- 229920000193 polymethacrylate Polymers 0.000 claims abstract 4
- 239000008107 starch Substances 0.000 claims abstract 4
- 235000019698 starch Nutrition 0.000 claims abstract 4
- 239000000126 substance Substances 0.000 claims abstract 4
- 235000012222 talc Nutrition 0.000 claims abstract 4
- 239000001993 wax Substances 0.000 claims abstract 4
- 239000000230 xanthan gum Substances 0.000 claims abstract 4
- 229920001285 xanthan gum Polymers 0.000 claims abstract 4
- 235000010493 xanthan gum Nutrition 0.000 claims abstract 4
- 229940082509 xanthan gum Drugs 0.000 claims abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract 2
- 239000007888 film coating Substances 0.000 claims abstract 2
- 238000009501 film coating Methods 0.000 claims abstract 2
- 230000030214 innervation Effects 0.000 claims abstract 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims 2
- 239000001856 Ethyl cellulose Substances 0.000 claims 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 239000011248 coating agent Substances 0.000 claims 1
- 238000000576 coating method Methods 0.000 claims 1
- 238000007907 direct compression Methods 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 229920001249 ethyl cellulose Polymers 0.000 claims 1
- 235000019325 ethyl cellulose Nutrition 0.000 claims 1
- 229960002870 gabapentin Drugs 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229960001233 pregabalin Drugs 0.000 claims 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims 1
- 239000004408 titanium dioxide Substances 0.000 claims 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
1. Фармацевтическая композиция для лечения нарушений иннерваций в форме таблетки, содержащая фампридин в качестве активного начала и вспомогательные вещества, отличающаяся тем, что в качестве вспомогательных веществ содержит вещество, замедляющее высвобождение, выбранное из группы, включающей гидроксипропилцеллюлозу, гидроксипропилметилцеллюлозу (гипромеллозу), метилцеллюлозу, гидроксиэтилцеллюлозу, ксантановую камедь или их смеси, связывающее вещество, выбранное из группы, включающей лактозу, крахмал, поливинилпирролидон, этилцеллюлозу, полиметакрилат, воски или их смеси, скользящий компонент, выбран из группы, включающей тальк, стеарат магния, стеарат кальция, стеариновую кислоту, или их смеси, при следующем содержании компонентов, мас.%:2. Фармацевтическая композиция по п.1, отличающаяся тем, что содержит 12,5 мг фампридина, в качестве вещества замедляющего высвобождение гидроксипропилметилцеллюлозу, в качестве связующего-поливинилпирролидон, в качестве скользящего - стеариновую кислоту при следующем содержании компонентов, мас.%:3. Фармацевтическая композиция по п.1, отличающаяся тем, что содержит в качестве вещества замедляющего высвобождение гидроксипропилметилцеллюлозу, в качестве связующего - поливинилпирролидон, в качестве скользящего - стеариновую кислоту при следующем содержании компонентов, мас.%:4. Фармацевтическая композиция по п.1, предназначенная для введения пациенту 2 раза в день - 1 раз в каждые 12 часов.5. Фармацевтическая композиция по п.1, отличающаяся тем, что она покрыта пленочной оболочкой.6. Фармацевтическая композиция по п.1, отличающаяся тем, что указанная композиция выполнена в фо�1. A pharmaceutical composition for treating innervation disorders in the form of a tablet containing fampridine as an active principle and excipients, characterized in that as excipients it contains a release inhibitor selected from the group consisting of hydroxypropyl cellulose, hydroxypropyl methyl cellulose (hypromellose), methyl cellulose, hydroxyethyl cellulose, xanthan gum or mixtures thereof, a binder selected from the group comprising lactose, starch, polyvinylpyrrolidone, ethyl cell yulozu, polymethacrylate, waxes or mixtures thereof, the sliding component is selected from the group consisting of talc, magnesium stearate, calcium stearate, stearic acid, or mixtures thereof, with the following component ratio, wt.%: 2. The pharmaceutical composition according to claim 1, characterized in that it contains 12.5 mg of fampridine, as a substance that slows the release of hydroxypropyl methylcellulose, as a binder, polyvinylpyrrolidone, and as a binder, stearic acid with the following content of components, wt.%: 3. The pharmaceutical composition according to claim 1, characterized in that it contains hydroxypropylmethyl cellulose as a substance that slows the release, polyvinylpyrrolidone as a binder, and stearic acid as a moving agent in the following components, wt.%: 4. The pharmaceutical composition according to claim 1, intended for administration to a patient 2 times a day - 1 time every 12 hours. The pharmaceutical composition according to claim 1, characterized in that it is coated with a film coating. The pharmaceutical composition according to claim 1, characterized in that said composition is made in ph
Claims (18)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013126056/15A RU2536269C1 (en) | 2013-06-06 | 2013-06-06 | Composition for treating disturbed innervation (versions) |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013126056/15A RU2536269C1 (en) | 2013-06-06 | 2013-06-06 | Composition for treating disturbed innervation (versions) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013126056A true RU2013126056A (en) | 2014-12-20 |
| RU2536269C1 RU2536269C1 (en) | 2014-12-20 |
Family
ID=53278060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013126056/15A RU2536269C1 (en) | 2013-06-06 | 2013-06-06 | Composition for treating disturbed innervation (versions) |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2536269C1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2607655C1 (en) * | 2015-09-25 | 2017-01-10 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Method of producing dalfampridin tablets with prolonged action |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2999990A1 (en) | 2015-09-29 | 2017-04-06 | Acorda Therapeutics, Inc. | Sustained release compositions of 4-aminopyridine |
| WO2018186866A1 (en) * | 2017-04-06 | 2018-10-11 | Cobb Joseph E Jr | Sustained release compositions of 4-aminopyridine |
| EP3687539A4 (en) * | 2017-09-25 | 2021-07-07 | Aizant Drug Research Solutions Private Limited | Stable pharmaceutical compositions of dalfampridine |
-
2013
- 2013-06-06 RU RU2013126056/15A patent/RU2536269C1/en active
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2607655C1 (en) * | 2015-09-25 | 2017-01-10 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Method of producing dalfampridin tablets with prolonged action |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2536269C1 (en) | 2014-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2014363599B2 (en) | Orally disintegrating solid dosage unit containing an estetrol component | |
| RU2016122609A (en) | COMPOSITIONS OF AZAINDOL COMPOUNDS | |
| RU2013140484A (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING AMINO COMPOUNDS | |
| KR20140075754A (en) | TABLET INCLUDING 7-[4-(4-BENZO[b]THIOPHEN-4-YL-PIPERAZIN-1-YL)BUTOXY]-1H-QUINOLIN-2-ONE OR SALT THEREOF | |
| IL305910B1 (en) | Formulation of an oral dosage form of }]5–(3–chlorophenyl)–3–hydroxypyridine–2–carbonyl[amino{acetic acid | |
| HRP20110125T1 (en) | Pharmaceutical compositions containing rosuvastatin calcium | |
| NZ753904A (en) | Compositions and methods for treating anemia | |
| EA201291410A1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING 4-AMINO-5-FTOR-3- [6- (4-METHILPIPERAZIN-1-IL) -1H-BENZIMIDAZOLE-2-IL] -1H-HINOLIN-2-SHE LOCTOT MONOHYTHA-2-IL] -1H-HINOLIN-2-SH-LYTOTOL-2-IL--1-IL-HYNOLIN-2-SH | |
| RU2013126056A (en) | COMPOSITION FOR TREATMENT OF INVERVATION DISORDERS (OPTIONS) | |
| RU2011152105A (en) | COMPOSITIONS OF 3-CYANOCHINOLINE TABLETS AND THEIR APPLICATION | |
| RU2014129508A (en) | NEW COMBINATION | |
| RU2007148195A (en) | ORAL DOSED FORMS OF O-DESMETHYLVENENLAFXIN SUCCINATE OF INCREASED BIOAVAILABILITY WITH DELAYED DELIVERY | |
| JP2016530238A5 (en) | ||
| HRP20100113T1 (en) | USE OF PREPARATIONS CONTAINING A CAP-OPIOID RECEPTOR ANTAGONIST INTENDED FOR THE TREATMENT OF Dissociative Disorders | |
| RU2011134964A (en) | PHARMACEUTICAL COMPOSITION CONTAINING ALEGLITAZAR | |
| JP2017520619A5 (en) | ||
| WO2014096982A1 (en) | Stable pharmaceutical compositions of saxagliptin or salts thereof | |
| HRP20150387T1 (en) | Choline and tromethamine salt of licofelone | |
| MY191983A (en) | Pharmaceutical formulations comprising sodium palmitoyl-l-prolyl-l-prolyl-glycyl-l-tyrosinate and methods for preparing the same | |
| RU2008115582A (en) | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF PARKINSON'S DISEASE | |
| JP7598213B2 (en) | Ramelteon-containing coated tablets | |
| RU2013120455A (en) | COMBINED DRUG FOR TREATMENT OF FUNGAL NAIL DISEASES | |
| RU2013124416A (en) | DIINDOLYLMETHANE MEDICINAL PRODUCT AND ITS APPLICATION FOR TREATMENT OF INFLUENZA AND RESPIRATORY VIRAL INFECTIONS | |
| RU2022105315A (en) | Composition of mirabegron and its use | |
| RU2006104035A (en) | SOLID MEDICINAL FORM OF DIINDOLYLMETHANE FOR THE TREATMENT OF NEOPLASTIC DISEASES |